Langenzersdorf, Austria

Franz Groiss

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2017-2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: **The Innovative Mind of Franz Groiss**

Introduction

Franz Groiss, a prolific inventor based in Langenzersdorf, Austria, has made significant contributions to the field of cancer treatment. With a focus on innovative methodologies, Groiss holds two patents that exemplify his commitment to advancing medical science.

Latest Patents

Groiss’ most notable inventions pertain to methodologies for treating GD2 positive cancer. His first patent details a novel approach where a preparation consisting of an anti-GD2 antibody is administered to patients as a continuous intravenous infusion over 24 hours per day. This groundbreaking method aims to enhance the efficacy of cancer treatment for patients suffering from this specific type of malignancy.

Career Highlights

Throughout his career, Franz Groiss has been associated with Apeiron Biologics AG, a company recognized for its pioneering efforts in immunotherapy. His work at Apeiron has placed him at the forefront of innovative biomedical research aimed at combating cancer.

Collaborations

In addition to his individual contributions, Groiss collaborates closely with esteemed colleagues, including Hans Loibner and Manfred Schuster. Together, they form a talented team dedicated to fostering advancements in therapeutic approaches and transforming patient care.

Conclusion

Franz Groiss stands out as an influential figure in the realm of cancer treatment innovations. His patents reflect a deep understanding of medical challenges and a determination to develop effective solutions. As the fight against cancer continues, inventors like Groiss play an essential role in shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…